Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials

Shoja, Zabihollah; Jalilvand, Somayeh; Latifi, Tayebeh; Roohvand, Farzin

doi:10.1007/s00705-022-05407-9

Cited by 12 publications

(7 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further confirmed that the induced anti-BRV VP6 antibodies exhibited cross-reactivity with a closely related, yet heterologous, Group A rotavirus strain, i.e., the simian rotavirus SA11 strain (Additional file 4 A). This cross-reactivity could be attributed to the substantial conservation of VP6 antigenicity among Group A rotaviruses [ 36 – 38 ]. Further, we confirmed neutralizing activity against the simian rotavirus using sera collected from mice inoculated with rNDV-WT-VP6 (Additional files 4 B–D).…”

Section: Resultsmentioning

confidence: 99%

Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein

Soliman,

Nishioka,

Murakoshi

et al. 2024

Vet Res

View full text Add to dashboard Cite

Numerous infectious diseases in cattle lead to reductions in body weight, milk production, and reproductive performance. Cattle are primarily vaccinated using inactivated vaccines due to their increased safety. However, inactivated vaccines generally result in weaker immunity compared with live attenuated vaccines, which may be insufficient in certain cases. Over the last few decades, there has been extensive research on the use of the Newcastle disease virus (NDV) as a live vaccine vector for economically significant livestock diseases. A single vaccination dose of NDV can sufficiently induce immunity; therefore, a booster vaccination dose is expected to yield limited induction of further immune response. We previously developed recombinant chimeric NDV (rNDV-2F2HN), in which its hemagglutinin-neuraminidase (HN) and fusion (F) proteins were replaced with those of avian paramyxovirus 2 (APMV-2). In vitro analysis revealed that rNDV-2F2HN expressing human interferon-gamma had potential as a cancer therapeutic tool, particularly for immunized individuals. In the present study, we constructed rNDV-2F2HN expressing the bovine rotavirus antigen VP6 (rNDV-2F2HN-VP6) and evaluated its immune response in mice previously immunized with NDV. Mice primarily inoculated with recombinant wild-type NDV expressing VP6 (rNDV-WT-VP6), followed by a booster inoculation of rNDV-2F2HN-VP6, showed a significantly stronger immune response than that in mice that received rNDV-WT-VP6 as both primary and booster inoculations. Therefore, our findings suggest that robust immunity could be obtained from the effects of chimeric rNDV-2F2HN expressing the same or a different antigen of a particular pathogen as a live attenuated vaccine vector.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein

Soliman,

Nishioka,

Murakoshi

et al. 2024

Vet Res

View full text Add to dashboard Cite

show abstract

“…Different groups could be found in different hosts. However, group A, also shown with Rotavirus A (RVA), was highly prevalent in humans, swine, and poultry ( 2 ). Epidemiologically, RV has a nearly 50-year history from the preliminary report in the State of Alaska to the present.…”

Section: Discussionmentioning

confidence: 99%

Commentary: Identification of pulmonary infections with porcine Rotavirus A in pigs with respiratory disease

Zhou

Niu²,

Zhang³

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

Generally speaking, fecal swabs and intestinal samples are candidates for detecting rotavirus, but not respiratory tissues such as the lungs, resulting in low detection rates or inaccurate test results. However, the routine was broken in a previous study (1). DiscussionRotavirus (RV) is one of the most important zoonotic pathogens for humans and other animals. Pathogenically, it is one of the predominant causes of high morbidity and mortality in enteric disease in infants and young animals. RV could be divided into 10 groups (from A to J) according to the VP6 gene. Different groups could be found in different hosts. However, group A, also shown with Rotavirus A (RVA), was highly prevalent in humans, swine, and poultry (2). Epidemiologically, RV has a nearly 50-year history from the preliminary report in the State of Alaska to the present. Nowadays, RV is not only prevalent in developed Frontiers in Veterinary Science frontiersin.org

show abstract

“…Likewise, the rotavirus capsid protein VP6 self-assembled VLP, which carried DOX by covalent conjunction also showed promising delivery of the drug into cultured cells. Modification of the VLP with lactobionic acid (LA) which binds to asialoglycoprotein receptors (ASGPRs) on the surface of the hepatoma cell line, showed specific delivery of the drugs to the HepG2 cells [51,79]. In addition, targeted delivery of the drug could be guided by single chain fragment variable (scFv) modified VLPs.…”

Section: Vlps For Compound Deliverymentioning

confidence: 99%

Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds

Lin

et al. 2022

Viruses

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nanostructures assemble from viral proteins. Besides widely used for vaccine development, VLPs have also been explored as nanocarriers for cargo delivery as they combine the key advantages of viral and non-viral vectors. While it protects cargo molecules from degradation, the VLP has good cell penetrating property to mediate cargo passing the cell membrane and released into cells, making the VLP an ideal tool for intracellular delivery of biomolecules and drugs. Great progresses have been achieved and multiple challenges are still on the way for broad applications of VLP as delivery vectors. Here we summarize current advances and applications in VLP as a delivery vector. Progresses on delivery of different types of biomolecules as well as drugs by VLPs are introduced, and the strategies for cargo packaging are highlighted which is one of the key steps for VLP mediated intracellular delivery. Production and applications of VLPs are also briefly reviewed, with a discussion on future challenges in this rapidly developing field.

show abstract

Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials

Cited by 12 publications

References 130 publications

Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein

Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein

Commentary: Identification of pulmonary infections with porcine Rotavirus A in pigs with respiratory disease

Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds

Contact Info

Product

Resources

About